Raptor Pharma (RPTP) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Raptor Pharmaceuticals (RPTP) PT Slashed to $5 at Wedbush; Difficulties Ahead
February 27, 2015 8:38 AM ESTWedbush analyst David Nierengarten reiterated an Underperform rating and cut his price target on Raptor Pharmaceuticals (NASDAQ: RPTP) to $5.00 (from $7.00) following Q4 results, saying decrease sales hints at difficulties ahead.
Nierengarten commented, "Raptor reported $17.3M in ww sales of Procysbi in 4Q, in line with our $16.9M... More



